The American Journal of
Managed Care
This supplement to contains information on benign prostatic hyperplasia, its available treatment, and clinical and economic implications of the disease. This supplement has been peer reviewed by experts in the field.
Faculty
LaKeasha R. Batiste, MS
Xcenda
Manager
GlaxoSmithKline
Senior Director
Palm Harbor, FL
Thomas C. Fenter, MD
University of Mississippi
Blue Cross & Blue Shield of Mississippi
Vice President
Palm Harbor, FL
Muta M. Issa, MD, MBA
Emory University School of Medicine
Medical Center
Professor of Urology
Director
Baltimore, MD
Timothy S. Regan, BPharm, RPh, CPh
Xcenda
Manager, USP Health Outcomes
Research Triangle Park, NC
Manan B. Shah, PharmD, PhD
Xcenda
Faculty Disclosures
These participants report relationships with the following pharmaceutical companies:
Libby Black, PharmD
Employee:
Thomas C. Fenter, MD
Lecture support from:
Consultant/advisory board/honorarium:
Consultant/advisory board, honoraria, and lecture support from:
M. Chris Runken, PharmD
Employee:
The American
Journal of Managed Care
It is the policy of to have all faculty who participate in programs sponsored by pharmaceutical companies disclose any real or apparent conflicts of interest.
GlaxoSmithKline provided funding to Xcenda to perform research and development related to this supplement. The authors listed here are employed by Xcenda, which receives grant support from GlaxoSmithKline and other pharmaceutical companies.
The American Journal of
Managed Care
Signed disclosures are on file at the office of , Princeton, New Jersey.
Funding
This supplement has been supported by funding from GlaxoSmithKline.
---
The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.